Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PTOC1 in Refractory Systemic Lupus Erythematosus
NCT07403097Phase 1Recruiting
- Sponsor
- Chongqing Precision Biotech
- Start
- Feb 2026
- Primary completion
- Apr 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of PTOC1 in systemic lupus erythematosus (SLE), sponsored by Chongqing Precision Biotech. Primary endpoints: Safety of PTOC1 cell therapy at 3 months, Changes in SLEDAI-2K from baseline at 6 months and 5 more. Started Feb 2026; status: recruiting.
02
Drugs
PTOC1
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT07403097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07403097.